NCT06269120View on ClinicalTrials.gov

SEMA-CardioDiab HUNGARY: A Research Study to Understand the Effects of Oral Semaglutide on Blood Sugar Levels, Weight, and Cardiovascular Risk in People With Type 2 Diabetes Patients in Hungary

RecruitingOBSERVATIONAL

Enrollment

470

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Type 2 Diabetes

Interventions

DRUG

Oral Semaglutide

Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.

Trial Locations (1)

7801

RECRUITING

Siklósi Kórház, Diabetológia, Siklós